[1]
Lazzari, G., Benevento, I., D’Andrea , B., Prudente, A., Brucoli, I., Bianculli, A., Tucciariello, R., Lerose, R., Metallo, V., Solazzo, A. and Montagna, A. 2025. The Impact of KEYNOTE-522 Related Immune-Related Adverse Events on Concurrent Adjuvant Whole Breast Radiotherapy in the Real World: A Case Series: KEYNOTE-522 and adjuvant hypofractionated RT. Archives of Breast Cancer. 12, 2 (Apr. 2025), 231–235. DOI:https://doi.org/10.32768/abc.2025122231-235.